Beyond the HLA typing age: genetic polymorphisms predicting transplant outcome

Area of Science:

• Immunogenetics
• Transplantation Science
• Molecular Biology

Background:

• Histocompatibility testing for human leukocyte antigens (HLA) is standard for donor selection in hematopoietic stem cell transplantation (HSCT).
• Non-HLA genes, including those encoding minor histocompatibility antigens, also critically influence HSCT outcomes.
• Genetic variations in non-HLA genes, particularly single nucleotide polymorphisms (SNPs) in regulatory regions, may affect post-transplant complications.

Purpose of the Study:

• To review current research on the role of non-HLA genes in predicting HSCT outcomes.
• To explore the impact of genetic variations in genes like Mannose Binding Lectin (MBL), myeloperoxidase (MPO), and Fcgamma receptors on post-transplant complications and infection control.
• To assess the potential clinical applications of these genetic findings in HSCT.

Main Methods:

• Literature review of recent studies on non-HLA gene polymorphisms and HSCT outcomes.
• Analysis of research focusing on SNPs in cytokine and cytokine receptor genes.
• Examination of studies investigating the role of MBL, MPO, and Fcgamma receptor genes in post-transplant infection control.

Main Results:

• Non-HLA minor histocompatibility antigens are crucial determinants of HSCT success beyond HLA matching.
• SNPs in regulatory regions of non-HLA genes, including those for cytokines, influence the severity of post-transplant complications.
• Genes such as MBL, MPO, and Fcgamma receptors are implicated in controlling post-transplant infections.

Conclusions:

• Genetic variations in non-HLA encoded genes offer valuable insights for predicting HSCT outcomes.
• Identifying specific SNPs may help stratify patients at risk for complications and infections.
• This genetic information holds potential for optimizing donor selection and patient management in HSCT.